HER2-Positive Breast Cancer, 1st Edition
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
特長
- Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive.
- Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations.
- Includes a timely section on innovative future therapies.
著者情報
| ISBN Number | 9780323581233 |
|---|---|
| Description Author List | By Sara Hurvitz, MD and Kelly McCann |
| Copyright Year | 2019 |
| Edition Number | 1 |
| Format | E-Book |
| Trim | Other |
| Imprint | Elsevier |
| Page Count | 0 |
| Publication Date | 26 Jul 2018 |
| Stock Status | IN STOCK |
Background/testing
1. The HER2 alteration in breast cancer
2. HER2 testing in the era of changing guidelines
Advanced Disease
3. Optimal first-line treatment of HER2+ advanced disease
4. Second line therapy and beyond
5. HER2+ CNS metastases
Therapeutics
6. Neoadjuvant therapy
7. Adjuvant therapy
8. Outcomes based on HR status in early stage disease
9. De-escalation of therapy for small tumor
Toxicity considerations
10. Cardiac toxicity of HER2-targeted regimens
11. Non-cardiac toxicity of HER2-targeted therapy
Therapies on the horizon
12. Targeting other pathways active in HER2+ disease (CDK4/6, VEGF, PI3K, mTOR, FGFR, PARP, antibody-drug conjugates, etc)
13. Harnessing the immune system in HER2+ disease
14. Biosimilars
